SYRE · Company research
Spyre Therapeutics, Inc. (SYRE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| SYRE Stock Technical Analysis - Pluang | SYRE Stock Technical Analysis Pluang | View source ↗ | Pluang | Oct 20, 2026 | neutral | 0 | 0.6 |
| Mouse studies found combinations of experimental bowel treatments worked better - Stock Titan | Mouse studies found combinations of experimental bowel treatments worked better Stock Titan | View source ↗ | Stock Titan | Oct 18, 2026 | neutral | 0 | 0.6 |
| Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 | Spyre Therapeutics announced presentations of clinical and preclinical data for its three IBD antibodies (SPY001, SPY002, and SPY003) at UEGW 2026 in Barcelona. The company presented efficacy and safety data for these half-life extended antibodies in moderately to severely active ulcerative colitis, along with preclinical evidence showing additive efficacy of combination approaches. The SKYLINE study is testing these candidates as monotherapies and pairwise combinations, with combination results expected in 2027. | View source ↗ | GlobeNewswire Inc. | Oct 18, 2026 | bullish | 1 | 1 |
| SYRE Jan 2027 105.000 put (SYRE270115P00105000) Stock Price, News, Quote & History - Yahoo! Finance Canada | SYRE Jan 2027 105.000 put (SYRE270115P00105000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 18, 2026 | neutral | 0 | 0.6 |
| SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits | SYRE Stock Marks Best Session In About 3 Years — Here’s Why Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| (SYRE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily | (SYRE) Movement Within Algorithmic Entry Frameworks Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 17, 2026 | neutral | 0 | 0.6 |
| A 60-day lock-up at Spyre Therapeutics (SYRE) bars Fairmount sales without underwriters’ consent. - Stock Titan | A 60-day lock-up at Spyre Therapeutics (SYRE) bars Fairmount sales without underwriters’ consent. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Spyre Therapeutics Announces Major Equity Financing Agreement - The Globe and Mail | Spyre Therapeutics Announces Major Equity Financing Agreement The Globe and Mail | View source ↗ | The Globe and Mail | Oct 8, 2026 | neutral | 0 | 0.6 |
| Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering - Yahoo Finance | Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock | Spyre Therapeutics priced its underwritten public offering at $85 per share, raising approximately $350 million in gross proceeds. The company plans to use the funds to advance its immunology programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and development of SPY072 for hidradenitis suppurativa. The offering is expected to close on October 7, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock | Spyre Therapeutics priced its underwritten public offering at $85 per share, raising approximately $350 million in gross proceeds. The company plans to use the funds to advance its immunology programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and development of SPY072 for hidradenitis suppurativa. The offering is expected to close on October 7, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| A proposed stock sale could help Spyre advance a new drug program into late-stage development. - Stock Titan | A proposed stock sale could help Spyre advance a new drug program into late-stage development. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock - Investing.com | Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock Investing.com | View source ↗ | Investing.com | Oct 2, 2026 | neutral | 0 | 0.6 |
| After exercising $14.50 options, Spyre Therapeutics (SYRE) CFO sells 25,000 shares. - Stock Titan | After exercising $14.50 options, Spyre Therapeutics (SYRE) CFO sells 25,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Spyre stock draws new Overweight at J.P. Morgan (SYRE:NASDAQ) - Seeking Alpha | Spyre stock draws new Overweight at J.P. Morgan (SYRE:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 1, 2026 | neutral | 0 | 0.6 |
| SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline - StocksToTrade | SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline StocksToTrade | View source ↗ | StocksToTrade | Sep 30, 2026 | neutral | 0 | 0.6 |
| SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations - Timothy Sykes | SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations Timothy Sykes | View source ↗ | Timothy Sykes | Sep 30, 2026 | neutral | 0 | 0.6 |
| SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - Yahoo Finance | SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis Yahoo Finance | View source ↗ | Yahoo Finance | Aug 26, 2026 | neutral | 0 | 0.6 |
| $SYRE stock is down 13% today. Here's what we see in our data. | SYRE Stock News - Quiver Quantitative | $SYRE stock is down 13% today. Here's what we see in our data. | SYRE Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 26, 2026 | neutral | 0 | 0.6 |
| Why Spyre Therapeutics (SYRE) Stock Is Up Today | SYRE Stock News - Quiver Quantitative | Why Spyre Therapeutics (SYRE) Stock Is Up Today | SYRE Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 14, 2026 | neutral | 0 | 0.6 |
| Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - Yahoo Finance | Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today Yahoo Finance | View source ↗ | Yahoo Finance | Jun 29, 2026 | neutral | 0 | 0.6 |
| Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE) - Yahoo Finance | Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE) Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.